**Table 7.** Summary of All Subjects With Biopsy Attempt

| **Case #** | **Age** | **Target Nodule, mm Axial, Sagittal, Coronal**  **(Largest diameter in bold)** | **Lesion Location** | **Nodule Density** | **EBUS Characteristic** | **Bronchus Sign** | **Initial Diagnosis  Study Sample**  **(Disease Status up to 6 months)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1c | 72 | 10.5, 8.4, **11.1** | RB1 | Solid | Eccentric | Present | Inconclusive  (Malignant)a |
| 2 | 54 | **16.7**, 14.6, 15.3 | RB4 | Solid | Eccentric | Absent | Inconclusive  (Benign Hamartoma)a |
| 3 | 66 | 6.7, **11.4**, 8.8 | LB3 | Solid | Concentric | Absent | Nodular Amyloidosis  (Benign)b |
| 4 | 70 | **13.1**, 9.4, 11.6 | RB9 | Solid | Concentric | Absent | Carcinoid  (Malignant) b |
| 5 | 73 | **19**, 14, 13 | RB3 | Solid | Eccentric | Absent | Carcinoid  (Malignant)a |
| 6 | 62 | 10.3, 7.7, **11** | RB10 | Solid | Eccentric | Present | Adenocarcinoma  (Malignant)a |
| 7 | 68 | 11.3, 9.2, **13.3** | LB3 | Solid | Eccentric | Absent | Non-small cell lung cancer  (Squamous cell carcinoma)a |
| 8 | 67 | 8.2, 8, **10.3** | RB1 | Semisolid/part-solid | Concentric | Absent | Benign Tumorlet + Foreign body type mulitnucleated cells  (Indeterminate) |
| 9 | 74 | **20.8**, 14.5, 14.8 | RB3 | Solid | Eccentric | Present | Adenocarcinoma  (Malignant)a |
| 10 | 75 | **11.5**, 13.6, 12.2 | LB 1+2 | Solid | Not Reported | Present | Non-small cell carcinoma  (Malignant)a |
| 11 | 57 | **12.6**, 9.5, 12.5 | LB6 | Solid | Eccentric | Present | Atypical cells\*  (Benign)b |
| 12 | 61 | **22**, 14.4, 11.7 | RB2 | Solid | Eccentric | Present | Inconclusive  (Benign)b |
| 13 | 59 | 13.4, **26.4**, 12.6 | LB3 | Solid | Concentric | Present | Adenocarcinoma  (Malignant)a |
| 14 | 72 | 12.8, **20.1**, 16.8 | LB3 | Solid | Eccentric | Absent | Adenocarcinoma  (Malignant)a |
| 15 | 50 | 10, **8.6**, 5.9 | LB 1+2 | Solid | Concentric | Absent | Neuroendocrine Tumor  (Malignant)a |
| 16 | 60 | 12, 11.7, **14.7** | RB2 | Ground Glass/nonsolid | Concentric | Present | Adenocarcinoma  (Malignant)a |
| 17 | 55 | **21.3**, 13.1, 8.7 | RB3 | Solid | Concentric | Present | Minimal Fibrosis  (Benign)b |
| 18 | 58 | 8.9, **11.1**, 10.4 | RB4 | Solid | Eccentric | Absent | Inconclusive  (Benign)a,b |
| 19 | 73 | **12.2**, 9.4, 9.6 | RB6 | Solid | Eccentric | Present | Non-small cell lung cancer  (Malignant)a |
| 20 | 63 | 10.2, 8.4, **21.1** | RB3 | Semisolid/part-solid | Concentric | Present | Adenocarcinoma  (Malignant)a |
| 21 | 46 | 7.3, 10, **10.5** | LB3 | Solid | Not visible | Absent | Inconclusive  (Malignant)a |
| 22 | 62 | 8.9, 4.5, **12.9** | RB6 | Semisolid/part-solid | Concentric | Absent | Multinucleated giant cells  (Benign)b |
| 23 | 53 | 7.9, 13.2, **19** | LB 1+2 | Semisolid/part-solid | Concentric | Present | Non-specific sub-bronchial fibrosis and organising changes including fibroblastic proliferation  (Benign)b |
| 24d | 22 | **14.3**, 8.7, 12.6 | RB5 | Solid | Eccentric | Present | Squamous cell carcinoma  (Malignant)a |
| 25 | 51 | 7.9, 10, **10.1** | RB2 | Solid | Eccentric | Absent | Nonspecific Granuloma  (Benign)b |
| 26 | 75 | **12.9**, 11.4, 11.9 | LB3 | Solid | Concentric | Present | Squamous cell carcinoma  (Malignant)a |
| 27 | 79 | 8.1, **12.4**, 11.3 | RB1 | Solid | Eccentric | Present | Adenocarcinoma  (Malignant)a |
| 28 | 70 | 10.8, **11.9**, 10.3 | LB10 | Solid | Concentric | Present | Adenocarcinoma  (Malignant)a |
| 29 | 41 | 15.4, 14.3, **17.4** | RB2 | Semisolid/part-solid | Concentric | Present | Inconclusive  (Benign)a |
| 30 | 67 | **10.8**, 9, 8.6 | RB10 | Solid | Concentric | Present | Non-specific inflammatory reactive changes  (Benign)a |

a Disease assessment confirmed through additional intervention or treatment decision, including surgery, CT-guided needle biopsy, chemotherapy, radiotherapy, ablation or palliative care

b Disease assessment confirmed through CT surveillance up to 6 months

c Subject represents 1st case where sample was not obtained

d Subject was excluded from final analysis due to violation of exclusion criteria – subject was exposed to radiotherapy approximately 11 weeks prior to study procedure

\*In addition to atypical cells, pathology report noted no malignant cells were seen